Projects per year
Fingerprint
Dive into the research topics where Asher A Chanan Khan is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Therapeutic implication of CD38 in CLL
Chanan Khan, A. A. & Chini, E. N.
9/4/19 → 8/31/22
Project: Research project
-
VACCINE FOR PATIENTS WITH NON HODGKINS LYMPHOMA
Chanan Khan, A. A. & Bernstein, S. H.
9/18/00 → 9/1/03
Project: Research project
-
Awareness of myeloma care and the global impact of treatment: An international internet-based prospective study
Ailawadhi, S., Swaika, A., Advani, P., Hodge, D., Paulus, A., Khera, N., Hashmi, S. K., Alegria, V. R., Abdulazeez, M., Bodepudi, S., Jamwal, K., Roy, V., Sher, T., Chanan-Khan, A. & Ailawadhi, M., Mar 2022, In: Journal of Oncology Pharmacy Practice. 28, 2, p. 425-433 9 p.Research output: Contribution to journal › Article › peer-review
-
Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma, Version 3.2022 Featured Updates to the NCCN Guidelines
Wierda, W. G., Brown, J., Abramson, J. S., Awan, F., Bilgrami, S. F., Bociek, G., Brander, D., Chanan-Khan, A. A., Coutre, S. E., Davis, R. S., Eradat, H., Fletcher, C. D., Gaballa, S., Ghobadi, A., Saad Hamid, M., Hernandez-Ilizaliturri, F., Hill, B., Kaesberg, P., Kamdar, M., Kaplan, L. D., & 14 others, Jun 2022, In: JNCCN Journal of the National Comprehensive Cancer Network. 20, 6, p. 622-634 13 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Dihydronicotinamide Riboside Is a Potent NAD+ Precursor Promoting a Pro-Inflammatory Phenotype in Macrophages
Chini, C. C. S., Peclat, T. R., Gomez, L. S., Zeidler, J. D., Warner, G. M., Kashyap, S., Mazdeh, D. Z., Hayat, F., Migaud, M. E., Paulus, A., Chanan-Khan, A. A. & Chini, E. N., Feb 25 2022, In: Frontiers in immunology. 13, 840246.Research output: Contribution to journal › Article › peer-review
Open Access -
Ibrutinib, lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma: Phase I trial results
Ailawadhi, S., Parrondo, R. D., Moustafa, M. A., LaPlant, B. R., Alegria, V., Chapin, D., Roy, V., Sher, T., Paulus, A. & Chanan-Khan, A. A., 2022, (Accepted/In press) In: Hematological Oncology.Research output: Contribution to journal › Article › peer-review
-
Plamotamab (XmAb®13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenström macroglobulinemia
Parrondo, R. D., Paulus, A., Alegria, V., Liebowitz, D., Johnson, C., Clynes, R., Roy, V., Menke, D. M., Jiang, L., Chanan-Khan, A. A. & Ailawadhi, S., 2022, In: Leukemia and Lymphoma. 63, 3, p. 738-742 5 p.Research output: Contribution to journal › Letter › peer-review